Advanced Methods for Cancer Detection by Vaginal Screening

Not Applicable

Completed

• Conditions: Endometrial Cancer; Ovarian Cancer
• Interventions: Other: Vaginal DNA Collection

• Registration Number: NCT02622776
• Lead Sponsor: Anna Tinker

Brief Summary

This pilot study is the first step in the development of an new assay that may be further tested as a screening method for ovarian and endometrial cancers.

Detailed Description

Most high grade ovarian cancers originate in the fallopian tubes. Since the lining of the fallopian tube opens into the uterine cavity cancer cells from ovarian/fallopian tube cancers can travel through the uterus to the cervix and vagina. Likewise, endometrial cancer cells shed through the cervix into the vagina. It may be possible to develop a screening test for ovarian and endometrial cancers by collecting vaginal cells.

Study Timeline

• Study First Submitted: 2015-12-01
• Study First Submitted QC: 2015-12-02
• Study First Posted: 2015-12-07
• Study Start: 2016-02
• Primary Completion: 2018-08
• Study Completion: 2018-12
• Status Verified: 2019-03
• Last Update Submitted: 2019-03-05
• Last Update Posted: 2019-03-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 122

Inclusion Criteria

Ovarian Cancer and Endometrial Cancer cases:

1. Women age 19 or older.
2. Histologically confirmed high grade serous cancer (had a pre-operative core biopsy) of ovarian/fallopian tube/peritoneal origin or histo-cytologically confirmed endometrial cancer, not yet treated by surgery or chemotherapy.
3. Give consent to access primary tumour tissue following surgery or biopsy.

Healthy participants:

1. Healthy women between the ages of 19 and 60.

Exclusion Criteria

Ovarian Cancer and Endometrial Cancer cases:

1. Women with self-reported, known pregnancy.

   Healthy participants:

2. Women with a prior diagnosis of gynecologic malignancy (ovarian, endometrial, cervical, or vulvar cancer) will be excluded.

3. Women who report irregular bleeding (spotting between menstrual cycles, or post-menopausal bleeding), or who have self-reported gynecologic concerns (e.g. pelvic pain, pelvic masses, dyspareunia) or have had a recent evaluation for gynecologic concerns (consultation with a gynecologist, pelvic ultrasound, endometrial biopsy) are ineligible.

4. Women with known Lynch Syndrome and/or BRCA1 or BRCA2 germline mutations will not be eligible to participate as healthy volunteers for this study.

5. Women with self-reported, known pregnancy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vaginal DNA Collection	Vaginal DNA Collection	Patients with a diagnosis of ovarian cancer or endometrial cancer who have not yet had surgery, chemotherapy or radiation may be able eligible to participate. Patients unaffected by cancer may be able to participate.

Primary Outcome Measures

Name	Time	Method
Patient Acceptance of the methods of DNA collection (Vaginal self-swab and tampon collection)	24 months	An 8 question questionnaire will be used to measure the acceptability of the DNA collection methods being used in this study (self-swab and tampon based collection)..
Assay sensitivity and specificity as assessed by the mutation detection rate in tumour and vaginal DNA	24 months	Vaginal DNA and tumour DNA will be compared to determine the mutation detection rate of the assay. Vaginal DNA from normal samples will determine if a background rate of somatic mutations is present in healthy women.

Trial Locations

Locations (1)

BC Cancer Agency; 🇨🇦 Vancouver, British Columbia, Canada